Aspirin and secondary mortality after myocardial infarction

Elwood, Peter Creighton and Sweetnam, P. M. 1979. Aspirin and secondary mortality after myocardial infarction. The Lancet 314 (8156) , pp. 1313-1315. 10.1016/S0140-6736(79)92808-3

Full text not available from this repository.

Abstract

A randomised controlled double-blind trial of aspirin in the prevention of death was conducted in 1682 patients (including 248 women) who had had a confirmed myocardial infarct (MI). 25% of the patients were admitted to the trial within 3 days of the infarction and 50% within 7 days. Aspirin, 300 mg three times daily, was given for 1 yr. Total mortality was 12·3% in patients given aspirin and 14·8% in those given placebo, a reduction by aspirin of 17%, which was not statistically significant at p<0·05. The reduction in specific ischæmic-heart-disease (IHD) mortality was 22% and in total mortality plus IHD morbidity (readmission to hospital for MI in survivors) was 28%.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Elsevier
ISSN:	0140-6736
Last Modified:	10 Jun 2023 01:24
URI:	https://orca.cardiff.ac.uk/id/eprint/65892

Citation Data

Cited 243 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item